Showing results (61-70 of 95) with videos related to
Sort By:
Pageof 10
Plos One|July 22, 2016
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter AnalysisRoberta Grande, Clara Natoli, Fabrizio Ciancola, et al.Cancer Treatment Reviews|January 3, 2015
Triple positive breast cancer: a distinct subtype?Patrizia Vici, Laura Pizzuti, Clara Natoli, et al.Clinical Breast Cancer|December 3, 2014
Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian surveyNicola Tinari, Caterina Fanizza, Marilena Romero, et al.Therapeutic Advances in Medical Oncology|August 28, 2019
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world settingAnna Di Benedetto, Cristiana Ercolani, Laura Pizzuti, et al.Journal of Cancer Research and Clinical Oncology|July 8, 2019
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyAlessandro Parisi, Alessio Cortellini, Michela Roberto, et al.British Journal of Cancer|November 1, 2018
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsFrancesco Passiglia, Federico Cappuzzo, Oscar Alabiso, et al.Journal of Cellular Physiology|May 18, 2016
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT TrialLaura Pizzuti, Maddalena Barba, Diana Giannarelli, et al.Journal of Cellular Physiology|October 10, 2015
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With EribulinMaddalena Barba, Laura Pizzuti, Isabella Sperduti, et al.Oncoimmunology|July 30, 2016
Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironmentSimonetta Buglioni, Patrizia Vici, Domenico Sergi, et al.Immunotherapy|March 23, 2018
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 studyAlessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.Pageof 10